IDEXX Expands Cancer Dx Panel to Include Mast Cell Tumor Detection for Dogs
Event summary
- IDEXX will add mast cell tumor detection to its Cancer Dx Panel in mid-2026, covering over one-third of canine cancer cases.
- The company is rolling out FNA cytology on its inVue Dx Cellular Analyzer for mast cell tumor detection by late Q4 2025.
- Over 5,500 veterinary practices in the U.S. and Canada already use the Cancer Dx Panel's lymphoma test.
- Mast cell tumor detection will be available at no additional cost with results in 2–3 days.
The big picture
IDEXX's expansion of its Cancer Dx Panel and the rollout of FNA cytology on its inVue Dx analyzer align with the broader trend of proactive cancer screening in veterinary medicine. The move positions IDEXX to capture a significant share of the canine cancer diagnostics market, which addresses over one-third of all canine cancer cases. The company's focus on rapid, in-clinic diagnostics also underscores the growing demand for timely and accurate cancer detection in pets.
What we're watching
- Adoption Pace
- How quickly veterinary practices will integrate the expanded Cancer Dx Panel into routine diagnostics.
- Diagnostic Accuracy
- Whether the new mast cell tumor detection capabilities will maintain the high sensitivity and specificity of the existing lymphoma test.
- Market Expansion
- The pace at which IDEXX will expand the FNA cytology capabilities beyond mast cell tumors.
Related topics